143 related articles for article (PubMed ID: 25618626)
1. Nivolumab provides favorable results in patients with advanced melanoma.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E11. PubMed ID: 25618626
[No Abstract] [Full Text] [Related]
2. Targeted programmed cell death in lung cancer treatment.
Zimmerman MP; Mehr SR
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E3. PubMed ID: 25618630
[No Abstract] [Full Text] [Related]
3. Melanoma drug wins US approval.
Ledford H
Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150
[No Abstract] [Full Text] [Related]
4. Dramatic Survival Benefit with Nivolumab in Melanoma.
Cancer Discov; 2016 Jun; 6(6):OF7. PubMed ID: 27091855
[TBL] [Abstract][Full Text] [Related]
5. American Association of Cancer Research Showcases Immunotherapy Advances.
Brower V
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
[No Abstract] [Full Text] [Related]
6. Nivolumab: Immunotherapy in Malignant Melanoma.
Bayless H; Schneider S
Clin J Oncol Nurs; 2015 Aug; 19(4):430-2. PubMed ID: 26207707
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
[TBL] [Abstract][Full Text] [Related]
8. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
Yamazaki N; Maeda Y
Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
[No Abstract] [Full Text] [Related]
9. PD-1-targeted immunotherapy: recent clinical findings.
Brahmer JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
[No Abstract] [Full Text] [Related]
10. Beyond ipilimumab: new approaches target the immunological synapse.
Garber K
J Natl Cancer Inst; 2011 Jul; 103(14):1079-82. PubMed ID: 21737695
[No Abstract] [Full Text] [Related]
11. PD-L1 expression as a potential predictive biomarker.
Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
Lancet Oncol; 2015 Oct; 16(13):1285-7. PubMed ID: 26433815
[No Abstract] [Full Text] [Related]
12. Nivolumab for the treatment of cancer.
Gunturi A; McDermott DF
Expert Opin Investig Drugs; 2015 Feb; 24(2):253-60. PubMed ID: 25494679
[TBL] [Abstract][Full Text] [Related]
13. Immunity unleashed in melanoma.
Erdmann MK
Lancet Oncol; 2010 Feb; 11(2):108-9. PubMed ID: 20152761
[No Abstract] [Full Text] [Related]
14. Immunotherapies in clinical trials: do they demand different evaluation tools?
Tuma RS
J Natl Cancer Inst; 2011 May; 103(10):780-1. PubMed ID: 21551417
[No Abstract] [Full Text] [Related]
15. Clinical development of the anti-CTLA-4 antibody tremelimumab.
Ribas A
Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
[TBL] [Abstract][Full Text] [Related]
16. Severe pneumonitis after nivolumab treatment in a patient with melanoma.
Watanabe S; Kimura H; Takato H; Waseda Y; Hara J; Sone T; Abo M; Maeda S; Matsushita T; Kasahara K
Allergol Int; 2016 Oct; 65(4):487-489. PubMed ID: 27184827
[No Abstract] [Full Text] [Related]
17. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
18. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-L1 antibody active in metastatic bladder cancer.
Brower V
Lancet Oncol; 2015 Jan; 16(1):e11. PubMed ID: 25638546
[No Abstract] [Full Text] [Related]
20. Alemtuzumab (Compath) off-label for relapsing multiple sclerosis.
Med Lett Drugs Ther; 2009 Mar; 51(1307):17-8. PubMed ID: 19265776
[No Abstract] [Full Text] [Related]
[Next] [New Search]